Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultibro Breezhaler in COPD (POWER)
NCT02202616Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of indacaterol, glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02202616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202616.